Detalles de la búsqueda
1.
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial.
Gastric Cancer
; 25(4): 783-793, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35352176
2.
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
Oncologist
; 24(3): 385-393, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30606884
3.
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Angiogenesis
; 15(2): 275-86, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22382585
4.
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Lancet Oncol
; 11(9): 845-52, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20702138
5.
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial.
Ther Adv Med Oncol
; 12: 1758835919899850, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32010236
6.
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Eur J Cancer
; 51(4): 473-481, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25637137
Resultados
1 -
6
de 6
1
Próxima >
>>